Sunesis Pharmaceuticals, Inc. (SNSS) Completes Enrollment in Phase 3 VALOR Trial of Vosaroxin in AML
9/25/2013 9:15:30 AM
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that enrollment in the company's pivotal, Phase 3 VALOR trial of vosaroxin plus cytarabine in first relapsed or refractory acute myeloid leukemia (AML) is now complete. Enrollment of 712 patients in the randomized, double-blind, placebo-controlled trial was achieved on schedule. Unblinding of the trial is expected in the first half of 2014 after reaching 562 events and locking the final study database.
Help employers find you! Check out all the jobs and post your resume.
comments powered by